Jul. 12 at 4:37 AM
$VTGN Catalysts for Vistagen’s Upward Trend Identified by AI
1. Discussions and Agreement on Future Development Direction (Path Forward) with the FDA
2. Results of the Fasedienol Phase 2 Repeated Dose Study (Expected Q3 2026)
3. Alignment of Safety Data for FDA New Drug Application (NDA)
4. Clinical Progress of Subsequent Pipelines (Repisolone, etc.)
